IRCT20210926052602N1 IRCT 2021-11-11 Kashan University of Medical Sciences Comparison of the effect of Metformin and Empagliflozin in treatment of prediabetic patients. Comparison of the effect of Metformin and Empagliflozin in treatment of prediabetic patients. 2021-10-22 anticipated 100 Complete https://irct.ir/trial/59281 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Screening, Randomization description: Patients were randomly divided (using the quadruple block method and through the website https://www.sealedenvelope.com/ to prepare a randomization list) into two groups of 50 people and a group treated with metformin 1000 mg daily and the other group are treated with empagliflozin 10 mg daily, Blinding description: This study is a single-blind study in which participants are unaware of the type of medication they receive. In order to perform blinding, the manufacturer was asked to prepare metformin and empagliflozin in exactly the same way (same color, same size, same packaging). The lead researcher and the physician are aware of the type of medication the patient is taking, but the person responsible for evaluating the statistical data will be unaware of this. 3 Prediabetes. Intervention 1: Intervention group 1: In this group, which includes 50 participants, empagliflozin tablets made by Actoverco Pharmaceutical Company are given 10 mg in a daily dose for three months. Intervention 2: Intervention group 2: In this group, which includes 50 participants, metformin tablets made by Abidi Pharmaceutical Company are given 1000 mg in a daily dose for three months. No - There is not a plan to make this available Justification or reason for not sharing IPD is No idea